Table 2.
Patterns of favipiravir exposure (n = 29).
| Number (%) orMedian (min/max) | |
|---|---|
| Time of exposure | |
| Preconception * | 2 (6.9%) |
| 1st trimester | 25 (86.2%) |
| 0- 3rd week | 3 (12.0%) |
| 3rd- 4th week | 7 (28.0%) |
| 4th- 5thweek | 12 (48.0%) |
| 5th- 6th week | 3 (12.0%) |
| 2nd trimester | 2 (6.9%) |
| Dose of favipiravir | |
| 3200 mg followed by 1200 mg/day | 26 (89.6%) |
| 1200 mg/day | 3 (10.3%) |
| 400 mg/day | 1 (3.4%) |
| Duration of exposure (day) | 5 (5–14) |
| Comedication | |
| No | 9 (31.0%) |
| Yes | 20 (69.0%) |
| NSAID | 8 (40.0%) |
| Hydroxychloroquine | 7 (35.0%) |
| Natural products | 6 (30.0%) |
| Paracetamol | 5 (25.0%) |
* Favipiravir was taken until 2nd and 3rd day before conception.